[go: up one dir, main page]

MX2018014753A - Therapeutic recombinant klotho proteins and compositions and methods involving the same. - Google Patents

Therapeutic recombinant klotho proteins and compositions and methods involving the same.

Info

Publication number
MX2018014753A
MX2018014753A MX2018014753A MX2018014753A MX2018014753A MX 2018014753 A MX2018014753 A MX 2018014753A MX 2018014753 A MX2018014753 A MX 2018014753A MX 2018014753 A MX2018014753 A MX 2018014753A MX 2018014753 A MX2018014753 A MX 2018014753A
Authority
MX
Mexico
Prior art keywords
klotho
protein
subject
dosage
same
Prior art date
Application number
MX2018014753A
Other languages
Spanish (es)
Inventor
F Tarsio Joseph
Raturi Dinesh
R Plante James
Original Assignee
Klotho Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klotho Therapeutics Inc filed Critical Klotho Therapeutics Inc
Publication of MX2018014753A publication Critical patent/MX2018014753A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Recombinant Klotho proteins and variants, nucleic acids encoding the same, cell lines and suspension cultures expressing the same, and method of manufacturing and administering the same are disclosed. Proteins include solubility or half-life-extending features like glycosylation and fusion protein tags. Proteins have at least 85% amino acid sequence identity to a portion of human alpha Klotho isoform 1. Treatment protocols include determining serum soluble Klotho level in a subject, calculating a dosage of the protein sufficient to raise the serum soluble Klotho level in the subject to a predetermined level, administering the dosage of protein to the subject, such as by bolus or gradual injection, determining a rate of Klotho protein decline in the serum of the subject following administration of the first dosage, calculating a time and amount of a subsequent dosage of the Klotho protein, and administering the subsequent dosage of Klotho protein to the subject.
MX2018014753A 2016-06-02 2017-06-02 Therapeutic recombinant klotho proteins and compositions and methods involving the same. MX2018014753A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662344743P 2016-06-02 2016-06-02
US201662375046P 2016-08-15 2016-08-15
US201662401600P 2016-09-29 2016-09-29
US201662425237P 2016-11-22 2016-11-22
US201762456318P 2017-02-08 2017-02-08
PCT/US2017/035755 WO2017210607A1 (en) 2016-06-02 2017-06-02 Therapeutic recombinant klotho proteins and compositions and methods involving the same

Publications (1)

Publication Number Publication Date
MX2018014753A true MX2018014753A (en) 2019-06-17

Family

ID=60477890

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018014753A MX2018014753A (en) 2016-06-02 2017-06-02 Therapeutic recombinant klotho proteins and compositions and methods involving the same.
MX2023008626A MX2023008626A (en) 2016-06-02 2018-11-29 Therapeutic recombinant klotho proteins and compositions and methods involving the same.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023008626A MX2023008626A (en) 2016-06-02 2018-11-29 Therapeutic recombinant klotho proteins and compositions and methods involving the same.

Country Status (9)

Country Link
EP (1) EP3464608A4 (en)
JP (3) JP2019526272A (en)
KR (2) KR102840156B1 (en)
CN (2) CN109219663A (en)
AU (1) AU2017272349B2 (en)
BR (1) BR112018073909A2 (en)
CA (1) CA3025461A1 (en)
MX (2) MX2018014753A (en)
WO (1) WO2017210607A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190088988A (en) * 2016-11-22 2019-07-29 클로토 테라퓨틱스, 아이엔씨. Novel recombinant clotto proteins and compositions and methods therefor
CN108333355B (en) * 2018-02-01 2020-05-26 黄曙 Use of KLOTHO protein in preparation of reagent for diagnosing risk of gastrointestinal stromal tumor
CN108384747A (en) * 2018-03-05 2018-08-10 安徽省农业科学院园艺研究所 Express the Chinese hamster ovary celI serum free suspension cultural method of Rabies virus antibody
CN109251896A (en) * 2018-08-13 2019-01-22 中山大学 The cell strain and its preparation method and application of one Expression of Plant Height hKLs-his albumen
CA3120701A1 (en) * 2018-11-21 2020-05-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for reducing age-related striated muscle and cognitive decline
WO2020160617A1 (en) * 2019-02-05 2020-08-13 Helium 3 Biotech Pty Ltd A membrane protein expression and distribution modulating composition and method of use thereof
RU2712770C1 (en) * 2019-05-21 2020-01-31 Всеволод Викторович Мелехин Method of inhibiting growth of tumor cells
IT201900007446A1 (en) 2019-05-29 2020-11-29 Giuseppe Castellano COMPOSITION INCLUDING CITRATE AND CARNITINE ABLE TO ACTIVATE THE PRODUCTION OF KLOTHO PROTEIN
AU2020398637A1 (en) * 2019-12-05 2022-06-30 President And Fellows Of Harvard College Methods for treating osteoarthritis
US11891615B2 (en) 2020-06-10 2024-02-06 Gail Marion Humble Process to produce Klotho protein in vitro
CN112195165A (en) * 2020-10-15 2021-01-08 广东药科大学 Anti-aging secretory Klotho protein, and coding gene, recombinant expression vector and application thereof
CN114487218B (en) * 2020-10-23 2023-11-14 北京红惠新医药科技有限公司 Analysis method of beta-nicotinamide mononucleotide
CN112915193B (en) * 2021-03-05 2022-09-13 南方医科大学南方医院 Application of KP-1 in preparation of medicine for treating chronic lung diseases
CN113444730A (en) * 2021-03-17 2021-09-28 昆明市延安医院 Screening and constructing method of primary hepatocyte klotho gene transduction stem cells
CN113215199A (en) * 2021-04-29 2021-08-06 广州博识生物科技有限公司 A Klotho+/- gene deletion zebrafish
WO2022243519A1 (en) * 2021-05-21 2022-11-24 Universitat Autònoma De Barcelona Secreted splicing variant of klotho for treating bone disorders
CN113409306A (en) * 2021-07-15 2021-09-17 推想医疗科技股份有限公司 Detection device, training method, training device, equipment and medium
WO2023172444A2 (en) * 2022-03-08 2023-09-14 Mayo Foundation For Medical Education And Research Senotherapeutic agents and alpha-klotho polypeptides
WO2023218445A1 (en) * 2022-05-08 2023-11-16 Ichilov Tech Ltd. Klotho derivatives with modified structure
WO2024115728A1 (en) * 2022-12-02 2024-06-06 Universitat Autònoma De Barcelona Secreted splicing variant of klotho for treating muscle disorders
CN116173077B (en) * 2023-03-21 2025-07-25 哈尔滨医科大学 Application of bifidobacterium animalis
EP4434534A1 (en) 2023-03-22 2024-09-25 ADvantage Therapeutics, Inc. Klotho mrna
CN117679530B (en) * 2023-11-13 2025-07-18 中国人民解放军陆军军医大学第二附属医院 A GP-pKlotho nano drug and its preparation method and application
EP4566618A1 (en) 2023-12-06 2025-06-11 ADvantage Therapeutics, Inc. Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight
WO2025109173A1 (en) 2023-11-22 2025-05-30 Advantage Therapeutics, Inc. Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027885A1 (en) * 1998-11-05 2000-05-18 Kyowa Hakko Kogyo Co., Ltd. Novel chimeric polypeptide
JP2001072607A (en) * 1999-09-03 2001-03-21 Kyowa Hakko Kogyo Co Ltd New method for improving vascular endothelial function
WO2001020031A2 (en) * 1999-09-10 2001-03-22 Kyowa Hakko Kogyo Co Ltd Polymorphisms in a klotho gene
DK1576182T4 (en) * 2002-12-23 2020-04-20 Bristol Myers Squibb Co PRODUCT QUALITY IMPROVEMENT BY PROCEDURE OF CULTIVATION OF PATTERN CELLS FOR PROTEIN PREPARATION
JP2006240990A (en) * 2003-05-15 2006-09-14 Kirin Brewery Co Ltd Klotho protein and anti-klotho protein antibody and uses thereof
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8420088B2 (en) * 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
CN102861343A (en) * 2012-10-17 2013-01-09 南方医科大学 Application of secretory type Klotho in preparing medicine for treating chronic renal failure
WO2014152993A1 (en) * 2013-03-14 2014-09-25 The Board Of Regents Of The University Of Oklahoma Use of klotho nucleic acids or proteins for treatment of diabetes and diabetes-related conditions
KR102459384B1 (en) * 2014-04-16 2022-10-26 주노 테라퓨틱스 게엠베하 Methods, kits and apparatus for expanding a population of cells

Also Published As

Publication number Publication date
CN116478907A (en) 2023-07-25
JP2023123565A (en) 2023-09-05
JP2019526272A (en) 2019-09-19
WO2017210607A1 (en) 2017-12-07
JP2025090742A (en) 2025-06-17
EP3464608A4 (en) 2020-01-29
CA3025461A1 (en) 2017-12-07
KR102570250B1 (en) 2023-08-29
EP3464608A1 (en) 2019-04-10
CN109219663A (en) 2019-01-15
AU2017272349B2 (en) 2022-12-01
BR112018073909A2 (en) 2019-02-26
KR102840156B1 (en) 2025-07-31
MX2023008626A (en) 2023-08-08
AU2017272349A1 (en) 2018-11-22
KR20190015711A (en) 2019-02-14
KR20230125857A (en) 2023-08-29

Similar Documents

Publication Publication Date Title
MX2023008626A (en) Therapeutic recombinant klotho proteins and compositions and methods involving the same.
MX2019005687A (en) Novel recombinant klotho proteins and compositions and methods involving the same.
EP4599847A3 (en) Prefusion coronavirus spike proteins and their use
WO2015024667A8 (en) Method for increasing expression of rna-encoded proteins
ZA202002094B (en) Trispecific proteins and methods of use
WO2021222639A3 (en) Recombinant human metapneumovirus f proteins and their use
DE23189888T1 (en) LIQUID PHARMACEUTICAL COMPOSITION OF ADALIMUMAB
EP4406585A3 (en) Nucleic acid products and methods of administration thereof
NZ711567A (en) Antibody formulations
MX2017014083A (en) Anti-cancer fusion polypeptide.
MX2017012506A (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF EYE DISEASES CONTAINING, AS ACTIVE INGREDIENT, A FUSION PROTEIN IN WHICH THE PEPTIDE THAT PENETRATES THE TISSUE AND THE PREPARATION OF THE ANTI-ASCULAR ENDOTELIAL GROWTH FACTOR IS FUSED.
HK1254450A1 (en) Novel fusion polypeptide specific for lag-3 and pd-1
EP4349360A3 (en) Peptide exhibiting wrinkle-improving activity and uses thereof
HRP20191966T1 (en) Stabilized non-protein clostridial toxin compositions
NZ749962A (en) Pegylated porcine interferon and methods of use thereof
CU24206B1 (en) FUSION PROTEINS THAT INCLUDE USEFUL FIBROBLAST GROWTH FACTOR IN METABOLIC DISORDERS
NZ621868A (en) Growth hormone polypeptides and methods of making and using same
MX390894B (en) ANTI-CANCER FUSION POLYPEPTIDE.
MX2021010039A (en) Novel fusion proteins specific for cd137 and gpc3.
MY200710A (en) Novel fusion protein specific for cd137 and pd-l1
HRP20171931T1 (en) Pharmaceutical formulation comprising a biopharmaceutical drug
RU2016105462A (en) METHODS AND COMPOSITIONS THAT PROVIDE MODULATION OF IMMUNE RESPONSES ASSOCIATED WITH THE INTRODUCTION OF A BIOPHARMACEUTICAL MEDICINE
MX387764B (en) PROCEDURE FOR REDUCING THE IMMUNOGENICITY OF PROTEINS AND PEPTIDES.
IN2014DN06920A (en)
WO2016122806A8 (en) Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life